成大醫院血液科臨床試驗

R/R acute leukemia (P1) or R/R AML per WHO 2022 (P2); molecularly selected (KMT2Ar or NPM1m); ECOG 0–2 (or adolescent PS ≥70)

Adults >=18 with LGLL or eligible cytotoxic lymphoma, ECOG and disease-specific prior-therapy requirements, adequate organ/coagulation function, and reproductive precautions; disease must be evaluable per protocol response frameworks.

R/R AML/ALL (± MLLr or NPM1m) with required disease/genomic confirmation; age >=18 (site exceptions), ECOG <=2, WBC below protocol threshold, adequate renal/hepatic function, life expectancy >=3 months, contraception/pregnancy requirements met.

Adults (>=18) with histologically confirmed r/r PTCL subtype, ECOG 0–2, prior systemic therapy failure/intolerance (with subtype-specific prior-therapy requirements), transplant-ineligible

Adults ≥18 with WHO 2016 MDS, IPSS-R very low/low/intermediate risk, BM blasts <5%, sEPO <500 U/L, RBC transfusion-dependent (2–6 units/8 wks), Hgb <11 g/dL, ECOG 0–2.

Adults with PMF/post-PV MF/post-ET MF, ECOG 0–2, TP53WT at randomization, ruxolitinib run-in response in suboptimal range, stable ruxolitinib dosing, protocol-defined hematologic/hepatic/renal function, and strict contraception requirements.

Adult (>=18) R/R FL1-3a or MZL after >=1 prior systemic line incl anti-CD20; measurable disease; ECOG 0-2; adequate marrow/organ function; informed consent; questionnaire/visit compliance; lenalidomide precautions.

Adults ≥18; MDS by WHO 2016, IPSS-R very-low/low/intermediate risk; transfusion-dependent (≥4 RBC units/16 wks); refractory/intolerant or unlikely to respond to ESAs; <5% marrow blasts; ECOG 0–2.

Adults ≥18 with measurable R/R multiple myeloma, 1–3 prior lines including an anti-CD38 antibody and lenalidomide, ECOG 0–2, adequate organ/marrow function, no prior BCMA/GPRC5D T-cell redirection.

Adults (>=18) with relapsed/refractory AML after multiple therapies, molecularly confirmed FLT3 or specified spliceosome mutations (SF3B1/SRSF2/U2AF1/ZRSR2), ECOG <=2, adequate hepatic/renal function